Special Issue

Behavioral Genetics of Addiction

Message from the Guest Editor

The implementation of genetic approaches into the research field of addiction and substance use disorders has greatly improved the understanding of the mechanisms underlying addiction and addictive behaviors. This Special Issue of the *Journal of* Personalized Medicine aims to highlight current progress in the field of the behavioral genetics of addiction by presenting the latest findings obtained from a variety of study designs. These studies will cover research work from both preclinical and clinical levels including, for example, transgenic rodent models, genetically selected rat/mice strains, or human populations using pharmacological, behavioral, or epigenetic approaches. The scientific advances in the field of behavioral genetics of addiction presented here support a personalized medicine approach to addiction treatments and pharmacotherapies that takes genedependent phenotypes into account. Ainhoa Bilbao

Guest Editor

Dr. Ainhoa Bilbao

- 1. Animal Facility and Animal Experimentation Unit, Biocruces Bizkaia Health Reseach Institute, 48903 Barakaldo, Spain
- 2. Central Institute of Mental Health, Faculty of Medicine Mannheim, University of Heidelberg, 68159 Mannheim, Germany

Deadline for manuscript submissions

closed (19 February 2022)



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/76014

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

<u>jpm</u>





Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

- 1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
- 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

